News
BTMD
6.01
+3.98%
0.23
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
NASDAQ · 4d ago
Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?
NASDAQ · 4d ago
Biote Settles Litigation and Repurchases Shares from Founder
TipRanks · 6d ago
BIOTE CORP - SETTLEMENT AGREEMENT INCLUDES A MUTUAL RELEASE OF ALL CLAIMS RELATING TO LITIGATION BETWEEN DONOVITZ AND BIOTE
Reuters · 6d ago
BIOTE CORP: TO REPURCHASE ALL OF FOUNDER'S 18.4 MLN SHARES AT $4.17 PER SHARE
Reuters · 6d ago
Biote Announces Definitive Settlement With Founder, Company To Repurchase All Of Founder's 18.4M Shares At $4.17 Per Share
Company to repurchase all of Founder's 18.4 million shares at $4.17 per share biote Corp. Announced it has entered into a definitive settlement agreement with Dr. Gary Donovitz. The settlement includes a mutual release of all claims relating to litigation between Biote and the founder of the company.
Benzinga · 6d ago
Biote announces definitive settlement with founder Gary Donovitz
Healthcare Biote announces definitive settlement with founder Gary Donovitz. Biote Corp. Will repurchase all 18.4 million shares beneficially held by the company's founder and stockholder of the company. The settlement includes a mutual release of all claims relating to litigation between the two companies.
Seeking Alpha · 6d ago
Biote Announces Definitive Settlement with Founder
Biote Corp. Has entered into a definitive settlement agreement with Dr. Gary Donovitz, founder and stockholder of Biote. The settlement includes a mutual release of all claims relating to litigation between the two companies. Biote will repurchase all 18.4 million Biote shares beneficially held by Donovitzer for $76.9 million in the aggregate.
Barchart · 6d ago
Weekly Report: what happened at BTMD last week (0422-0426)?
Weekly Report · 6d ago
Press Release: Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
Biote Schedules First Quarter 2024 Financial Results Release and Conference Call. Biote is a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness. The company will provide first quarter financial results on May 7, 2024, after the close of the market.
Dow Jones · 04/23 20:25
Weekly Report: what happened at BTMD last week (0415-0419)?
Weekly Report · 04/22 09:42
Weekly Report: what happened at BTMD last week (0408-0412)?
Weekly Report · 04/15 09:39
Weekly Report: what happened at BTMD last week (0401-0405)?
Weekly Report · 04/08 09:41
Weekly Report: what happened at BTMD last week (0325-0329)?
Weekly Report · 04/01 09:41
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. Sunshine Biopharma stock moved upwards by 39.5% as the company's market cap rose to $8.3 million. Xilio Therapeutics and Medpace Hldgs also rose in the wake of Q4 earnings.
Benzinga · 03/29 20:30
Weekly Report: what happened at BTMD last week (0318-0322)?
Weekly Report · 03/25 09:42
Weekly Report: what happened at BTMD last week (0311-0315)?
Weekly Report · 03/18 09:41
Optimistic Outlook: Biote’s Growth Potential and Strategic Initiatives Despite Transitional Challenges
TipRanks · 03/15 01:15
Biote Corp. Releases March 2024 Investor Presentation
TipRanks · 03/14 20:24
Biote Soars 22% With Expected Acceleration in 2H 2024 Sales
Biote stock increased nearly 22% to $6.49 in midday trading. Shares of Biote are up 31.6% year to date. The hormone therapy company says it expects growth to accelerate in the second half of 2024. The company expects full-year 2024 revenue between $200 million and $204 million.
Dow Jones · 03/13 16:13
More
Webull provides a variety of real-time BTMD stock news. You can receive the latest news about Biote through multiple platforms. This information may help you make smarter investment decisions.
About BTMD
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.